GSK to acquire Nuvalent for $10.6 billion in cash deal
GSK Plc announced the acquisition of clinical-stage precision oncology company Nuvalent, Inc for $10.6 billion in cash, representing a 40% premium. Deerfield Management, Nuvalent's founding investor, funded the company's early development and will donate upwards of $200 million in profits to its foundation. Nuvalent's shares surged 39.28% on the news.
*this image is generated using AI for illustrative purposes only.
Nuvalent, Inc shares surged 39.28% to $123.25 during Tuesday's trading session, closing near their intraday high of $123.62. The rally followed GSK Plc's announcement that it will acquire the clinical-stage precision oncology company for $10.6 billion in cash, or $124 per share. This price represents a 40% premium over Nuvalent's closing share price on Monday. The transaction provides GSK with two late-stage, potential best-in-class ROS1 and ALK inhibitors for the treatment of non-small cell lung cancer, designed to overcome drug resistance and toxicity.
Deerfield Management, an investment firm dedicated to advancing healthcare, announced that its portfolio company Nuvalent has entered into a definitive agreement to be acquired by GSK. As the sole founding investor, Deerfield seeded Nuvalent in 2017 and funded the entirety of the company's $50 million Series A beginning in 2018. The firm subsequently supported a $135 million Series B in May 2021 before Nuvalent launched a public offering in July 2021. Deerfield's profits from this investment, expected to be upwards of $200 million, will be donated to the Deerfield Foundation, a private not-for-profit organization.
Strategic Context and Leadership
Nuvalent was founded in 2017 by Deerfield in collaboration with Matthew Shair, PhD, a chemical biologist and Harvard University professor. The company is led by Chief Executive Officer James Porter, PhD. Management attributes the company's success to a structure-based small molecule design combined with clinical insights, aiming to address brain metastases and drive durable responses for patients.
Market Performance
The broader market finished mixed on Tuesday. The Dow Jones Industrial Average gained 0.17% to 50,872.11, while the S&P 500 slipped 0.26% to 7,386.65 and the Nasdaq fell 0.97% to 25,678.82. Despite the market dip, Nuvalent's performance stood out as one of the top movers of the day.
| Company | Price | Change | 52-Week Range |
|---|---|---|---|
| Nuvalent, Inc | $123.25 | +39.28% | $71.14 – $123.62 |
| Super Micro Computer Inc. | $40.64 | -7.62% | $19.49 – $62.36 |
| DraftKings Inc. | $27.59 | +11.34% | $20.46 – $48.78 |
| Cracker Barrel Old Country Store, Inc. | $36.30 | +6.11% | $24.85 – $71.93 |
| Oracle Corporation | $205.81 | -2.84% | $134.57 – $345.72 |
How will this $10.6 billion acquisition impact GSK's R&D budget and pipeline prioritization for other therapeutic areas?
What regulatory milestones must the ROS1 and ALK inhibitors clear to justify the 40% premium paid by GSK?
Will this deal trigger a new wave of consolidation among clinical-stage precision oncology companies?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
